Dnl151

DNL151 / Denali Therap, Biogen

DNL151 « New Drug Approvals

Denali, Biogen Partner to Move DNL151 Into Late-stage Parkinson's Trials

DNL151 / Denali Therap, Biogen

DNL151 / Denali Therap, Biogen

DNL151 – The Science of Parkinson's

DNL151 / Denali Therap, Biogen

Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s ...

Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估-MedSci.cn

LRRK2 in Parkinson's disease: upstream regulation and therapeutic ...

ScienceofParkinsons on Twitter: "The summary slides of the lysosomal ...

The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2 ...

Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s ...

Document

The luminance of a lighthouse – The Science of Parkinson's

figure10.jpg

LRRK2-targeted treatments including LRRK2 inhibitors and antisense ...

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for ...

dnli-20201231

BIIB122 – The Science of Parkinson's

dnli-20191231

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung ...

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

2 Parkinson's Trials to Test Oral BIIB122/DNL151 in Slowing Progression

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

Breakthrough Ideas for Parkinson’s Disease Treatment - Creative Diagnostics

A step forward for LRRK2 inhibitors in Parkinson’s disease | Science ...

Frontiers | Development of mutation-selective LRRK2 kinase inhibitors ...

LRRK2抑制剂——帕金森病的明日之星|抑制剂|帕金森病|LRRK2|蛋白|磷酸化|-健康界

LRRK2 and idiopathic Parkinson’s disease: Trends in Neurosciences

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

LRRK2抑制剂——帕金森病的明日之星 文章来源：“ 凯莱英 药闻”微信公众号帕金森病（Parkinson′s disease，PD）是第二 ...

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for ...

(DNL-151)-药物靶点：LRRK2_专利_临床_研发

LRRK2 and Parkinson's disease: from genetics to targeted therapy ...

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

Our Parkinson's Place: First Parkinson’s Patient Dosed in Early Trial ...

Oral Therapy BIIB122/DNL151 Dosed in Parkinson's Clinical Trial LUMA

Oral Therapy BIIB122/DNL151 Dosed in Parkinson's Clinical Trial LUMA

2 Parkinson's Trials to Test Oral BIIB122/DNL151 in Slowing Progression

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

Oral Parkinson's Therapy Safely Lowers LRRK2 Activity in Phase 1 Trials

DNL-151(DNL-151) - 药物靶点：LRRK2_在研适应症：帕金森病_专利_临床_研发

LRRK2 Inhibitor | LRRK2 Inhibitor Review

Structure-Based Virtual Screening and De Novo Design to Identify ...

Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich ...

LRRK2抑制剂——帕金森病的明日之星|抑制剂|帕金森病|LRRK2|蛋白|磷酸化|-健康界

Design of an LRRK2 inhibitor-desensitized mutant (A) Structural model ...

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for ...

Smartphone-based digital assessments in the LUMA trial of BIIB122 ...

Frontiers | Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics

Inhibition of Parkinson’s disease–related LRRK2 by type I and type II ...

LRRK2抑制剂——帕金森病的明日之星|抑制剂|帕金森病|LRRK2|蛋白|磷酸化|-健康界

LRRK2抑制剂——帕金森病的明日之星|抑制剂|帕金森病|LRRK2|蛋白|磷酸化|-健康界

Denali Initiates Phase 2a Trial for LRRK2 Inhibitor in Parkinson's

用于 PD 治疗的小分子 LRRK2 抑制剂：当前成就和未来展望,European Journal of Medicinal ...

LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ...

Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the ...

metabolicprofiling11.jpg

LRRK2 and idiopathic Parkinson’s disease: Trends in Neurosciences

dnli-20191231

Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s ...

LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ...

帕金森病治疗的一大步：LRRK2抑制剂临床试验评估|帕金森病|LRRK|DNL|患者|抑制剂|-健康界

Parkinson's Disease Therapeutics Conference | Parkinson's Disease

News in Context: LRRK2 Therapies Speeding Forward after $1B Biotech ...

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 ...

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease

Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the ...

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for ...

New publication: LRRK2 Inhibition by BIIB122 in Healthy Participants ...

LOGO

Nature Reviews Drug Discovery on Twitter: "LRRK2-targeted Parkinson ...

Capturing Differences in the Regulation of LRRK2 Dynamics and ...

Deal: Biogen to co-develop and co-commercialize LRRK2 inhibitors with ...

Denali Therapeutics Continues To Have Plenty Of Moving Parts (NASDAQ ...

Efficacy and pharmacodynamic properties of the LRRK2 kinase inhibitor ...

LOGO

Deal: Biogen to co-develop and co-commercialize LRRK2 inhibitors with ...

Inhibiting LRRK2: The Denali Phase I results – The Science of Parkinson's

默沙东LRRK2抑制剂的优化-MedSci.cn

Denali Initiates Phase 2a Trial for LRRK2 Inhibitor in Parkinson's

Target familial PD genes that contribute to a-synuclein toxicity -LRRK2 ...

The ibuprofen post – The Science of Parkinson's

Inhibiting LRRK2: The Denali Phase I results – The Science of Parkinson's

进击的LRRK2—筹码加大，渤健下注10亿美元，牵手神经科学新锐Denali - 药时代DrugTimes

Parkinsonism & Related Disorders

Rab10 and pRab10 immunofluorescence and confocal microscopy images in ...

LRRK2 kinase inhibitor (GSK) treatment abolished Drp1 increase and ...

默沙东LRRK2抑制剂的优化-MedSci.cn

Type II kinase inhibitors that target Parkinson’s disease–associated ...

LOGO

LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at ...

Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s ...

Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in ...

First Patient Treated in Phase 2a Trial of Investigational BIIB122 for ...

Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration ...

Nanobodies as allosteric modulators of Parkinson’s disease–associated ...

Progression and summary of LRRK2 small molecule kinase inhibitor ...

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study ...

LRRK2-targeted Parkinson disease drug advances into phase III

LRRK2-IN-1 inhibits DCLK1 kinase activity. An in vitro kinase assay was ...

Exploring the damage of mtDNA – The Science of Parkinson's

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease

Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration ...

Characterization of a selective inhibitor of the Parkinson’s disease ...

Small Molecules in Parkinson’s Disease Therapy: From Dopamine Pathways ...

D151

titles1.jpg

LRRK2-targeted treatments including LRRK2 inihibitors and antisense ...

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s ...

Type II kinase inhibitors that target Parkinson’s disease–associated ...

Structure-Based Virtual Screening and De Novo Design to Identify ...

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s ...

Denali Therapeutics Biogen Initiate Phase 2B Study Of Lrrk2 Inhibitor ...

Important phase 1 trial results for LRRK2 inhibitor drug - Cure Parkinson's

MAPK signaling pathway - Cusabio

Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s ...

Stabilization and inhibition of LRRK2's kinase by type-I and type-II ...